Effects of Baduanjin Exercise on Antihypertensive Medication Reduction in Older Patients with Hypertension: A Study Protocol for a Randomized Controlled Trial

Author: Ran Zhao1,2, Shengjie Yang1, Dan Li1, Longtao Liu3, Yanwei Xing1, Min Wu1
Affiliation:
1 Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
2 Beijing University of Chinese Medicine, Beijing, China.
3 Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Conference/Journal: Evid Based Complement Alternat Med
Date published: 2021 Jul 22
Other: Volume ID: 2021 , Pages: 8663022 , Special Notes: doi: 10.1155/2021/8663022. , Word Count: 209


Background:
Hypertension is a serious global public health problem, and its incidence increases with age. Research has suggested that multiple antihypertensive prescriptions may be harmful to older individuals with hypertension. Baduanjin, a widely practiced physical activity in China, has been used as an adjuvant therapy to antihypertensive treatment in older individuals with hypertension. Therefore, the aim of the current study is to investigate whether Baduanjin exercise could reduce the need for antihypertensive medications in older patients.

Methods:
This single-center, open, randomized controlled trial will be conducted in China. Seventy eligible participants will be randomly assigned to either the 12-week Baduanjin exercise group or the 12-week aerobic exercise group (5 times a week), at a ratio of 1 : 1. The primary outcome will include the proportion of participants who reduce their antihypertensive medications. The secondary outcomes will include the changes in mean office systolic and diastolic pressure, 24-h ambulatory blood pressure, health-related quality of life (based on SF-36), and gut microbiota composition. Discussion. The results of this study will provide powerful evidence for the use of Baduanjin as an adjuvant therapy for antihypertensive medication reduction in older people with hypertension and therefore find the best treatment for hypertension. This trial is registered in the Chinese Clinical Trials Registry (ChiCTR1900024429).


PMID: 34335840 PMCID: PMC8324341 DOI: 10.1155/2021/8663022

BACK